Zepbound and Wegovy are two of the most widely discussed prescription medications for chronic weight management. Both are injectable therapies that work through incretin hormone pathways, but they differ in mechanism, average weight loss outcomes, dosing schedules, and cost. Understanding these differences helps patients and clinicians make informed, individualized treatment decisions.
At a Glance
| Criterion | Zepbound | Wegovy |
|---|---|---|
| Active Ingredient | Tirzepatide | Semaglutide |
| FDA Approval (Weight) | November 2023 | June 2021 |
| Drug Class | GIP/GLP-1 dual agonist | GLP-1 receptor agonist |
| List Price (monthly) | ~$1,059 | ~$1,349 |
| Dosing Frequency | Once weekly | Once weekly |
| Dose Range | 2.5 mg – 15 mg | 0.25 mg – 2.4 mg |
| Average Weight Loss (trials) | ~20–22% body weight | ~15–17% body weight |
| Cardiovascular Indication | In review (SURMOUNT-MMO ongoing) | FDA-approved (March 2024) |
| Availability | Widely available; periodic shortages | Widely available; periodic shortages |
| Best For | Patients prioritizing maximum weight loss; those with type 2 diabetes | Patients with established cardiovascular disease; longer real-world track record |
Active Ingredient
Zepbound contains tirzepatide, a first-in-class dual agonist that activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors simultaneously. This dual mechanism is thought to produce stronger appetite suppression and metabolic effects than activating the GLP-1 pathway alone. Eli Lilly markets the same molecule as Mounjaro for type 2 diabetes.
Wegovy contains semaglutide, a GLP-1 receptor agonist developed by Novo Nordisk. Semaglutide selectively targets GLP-1 receptors, slowing gastric emptying, reducing appetite, and improving insulin secretion. The same molecule at a lower dose is marketed as Ozempic for type 2 diabetes. Semaglutide has a longer established track record in clinical use across both indications.
FDA Approval
Wegovy received FDA approval for chronic weight management in adults in June 2021, making it the earlier-approved option with a longer period of post-market safety surveillance. In March 2024, the FDA extended Wegovy's label to include reducing the risk of serious cardiovascular events (heart attack, stroke) in adults with obesity or overweight and established cardiovascular disease — a significant clinical milestone backed by the SELECT trial.
Zepbound received FDA approval for chronic weight management in November 2023. It is approved for adults with a BMI of 30 or greater, or 27 or greater with at least one weight-related comorbidity. Eli Lilly is currently conducting the SURMOUNT-MMO cardiovascular outcomes trial, and results are anticipated in the coming years. Zepbound does not yet carry an FDA-approved cardiovascular risk reduction indication.
Cost
At list price, Zepbound runs approximately $1,059 per month and Wegovy approximately $1,349 per month, though actual out-of-pocket costs vary considerably based on insurance coverage, employer benefits, and manufacturer savings programs. Eli Lilly offers a savings card that can reduce Zepbound's cost to as low as $550 per month for eligible commercially insured patients, and Novo Nordisk offers a similar program for Wegovy. Neither drug is broadly covered by Medicare Part D for weight management as of early 2024, though this is subject to legislative change.
Compounded versions of both tirzepatide and semaglutide have proliferated through telehealth platforms, often at significantly lower prices. These compounded formulations are not FDA-approved products, carry different risk profiles, and exist in a shifting regulatory landscape. The FDA has removed semaglutide from its drug shortage list, which may restrict compounding access for that molecule going forward.
Dosing
Both medications are administered once weekly via subcutaneous injection using a prefilled auto-injector pen. Zepbound starts at 2.5 mg weekly for the first four weeks, then escalates in 2.5 mg increments every four weeks as tolerated, up to a maintenance dose of 10 mg or 15 mg. The slower escalation schedule is designed to minimize gastrointestinal side effects during dose increases.
Wegovy begins at 0.25 mg weekly for the first four weeks and escalates through four dose levels over approximately 16–20 weeks, reaching the target maintenance dose of 2.4 mg. The dose units are not directly comparable between the two drugs given their different molecular structures and potencies. Both follow a titration-first approach to improve tolerability.
Clinical Efficacy
In the SURMOUNT-1 trial, adults without diabetes taking the highest dose (15 mg) of tirzepatide lost an average of approximately 22.5% of body weight over 72 weeks. Across both the 10 mg and 15 mg doses, average weight loss ranged from roughly 20–22%. A head-to-head trial (SURMOUNT-5) comparing tirzepatide and semaglutide directly has reported preliminary results suggesting greater average weight loss with tirzepatide, though individual responses vary.
In the STEP-1 trial, adults without diabetes taking semaglutide 2.4 mg lost an average of approximately 14.9% of body weight over 68 weeks. Real-world data have broadly confirmed these trial results. The SELECT cardiovascular outcomes trial — which enrolled over 17,600 participants — demonstrated a 20% reduction in major adverse cardiovascular events with semaglutide compared to placebo, supporting the expanded FDA label for cardiovascular risk reduction.
Side Effects
The side effect profiles of both medications are similar, reflecting their shared GLP-1 mechanism. The most common adverse effects include nausea, vomiting, diarrhea, constipation, and abdominal discomfort. These effects are most pronounced during dose escalation and typically diminish over time. Both drugs carry class-level warnings regarding a potential risk of thyroid C-cell tumors (based on rodent studies), pancreatitis, and gallbladder disease.
Because tirzepatide also activates the GIP receptor, some researchers have speculated that its dual mechanism could produce a distinct side effect profile, though clinical trial data have not revealed dramatically different safety signals compared to semaglutide. Both prescribing labels advise against use in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Availability
Both Zepbound and Wegovy have faced supply shortages since their respective launches, driven by high demand outpacing manufacturing capacity. As of 2024, availability has improved for both drugs, though regional shortages of specific doses can still occur. Patients are advised to confirm stock with their pharmacy before initiating or switching doses. Both medications are available at major retail and specialty pharmacies across the United States.
International availability differs significantly. Wegovy is approved and available in more countries globally, given its earlier approval timeline and Novo Nordisk's longer manufacturing history for semaglutide. Zepbound's international rollout is ongoing, and it may be marketed under different brand names in other markets. Patients outside the US should verify local regulatory status with their healthcare provider.
Key Takeaway
The core difference between Zepbound and Wegovy lies in their mechanism and outcomes data: Zepbound's dual GIP/GLP-1 agonism is associated with greater average weight loss in clinical trials, while Wegovy holds a longer approval history, more extensive real-world safety data, and an FDA-approved cardiovascular risk reduction indication backed by a large outcomes trial. Both are once-weekly injections with similar side effect profiles and broadly comparable access challenges. The right choice for any individual depends on their medical history, cardiovascular risk factors, insurance coverage, and response to treatment — factors best evaluated with a qualified prescriber.